Patents Examined by Jeanine A. Goldberg
  • Patent number: 11512352
    Abstract: Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: November 29, 2022
    Assignee: Athena Diagnostics, Inc.
    Inventors: Corey D. Braastad, Narasimhan Nagan, Jeffrey G. Jones, William K. Seltzer, Susan K. Allen, Sat Dev Batish, Hui Zhu
  • Patent number: 11505818
    Abstract: The present application relates to detection units and methods for detecting one or more target analytes in a sample using a complex formed by a target and first and second probes, wherein the complex comprises an elongated region, a particle that is coupled to the first probe, and a solid support that is coupled to the second probe. Specific binding of a target analyte can be distinguished from non-specific binding of the particle by measuring the displacement of the particle.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 22, 2022
    Assignee: Scanogen Inc.
    Inventors: Alfredo Andres Celedon, Saravana Radha Krishna Murthy, Zhiguang Xu, Danielle Elise Schultz, Troy Allen Horn
  • Patent number: 11492655
    Abstract: A method of detecting a nucleic acid including a) mixing a solution containing a carboxylic acid and/or a salt thereof, a cerium oxide support and a sample containing a nucleic acid to adsorb said nucleic acid to said cerium oxide support, b) separating said cerium oxide support on which said nucleic acid was adsorbed from the mixture obtained in a), c) collecting said nucleic acid by adding an eluent to said cerium oxide support on which said nucleic acid was adsorbed and separated in b), and d) detecting said nucleic acid collected in c) by a hybridization reaction or a nucleic acid amplification reaction.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 8, 2022
    Assignee: Toray Industries, Inc.
    Inventors: Shota Sekiguchi, Mai Nakagawa, Masateru Ito, Shinjiro Sawada
  • Patent number: 11466325
    Abstract: Methods for determining the presence or absence of expansion of CGG repeat sequence in the FMR1 gene presence or absence of expansion of CCG repeat sequence in the FMR2 gene are provided. The methods are useful in identifying an individual with normal/intermediate, versus premutation or full mutation allele of FMR1 gene and FMR2 gene due to the expansion of CGG repeats and CCG repeats in the 5?-untranslated region respectively. The methods are also useful for screening newborns for fragile X syndrome or for screening women to determine heterozygosity status with full premutation of the CCG repeat tract. The methods are also useful in estimating the premutation and full mutation carrier frequency and estimating the prevalence of FXTAS AND FXPOI in a population. The methods are simple, rapid and require small amount of sample.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: October 11, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Feras Hantash, Weimin Sun, David C. Tsao, Dana Marie Root, Charles M Strom
  • Patent number: 11459618
    Abstract: A panel of gene expression markers for gastric cancer patient treated or to be treated by cetuximab is provided. Methods and compositions are also provided, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to predict a gastric cancer patient's response to cetuximab.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: October 4, 2022
    Assignee: CROWN BIOSCIENCE, INC. (TAICANG)
    Inventors: Binchen Mao, Sheng Guo, Henry Qixiang Li
  • Patent number: 11441187
    Abstract: Disclosures herein encompass methods of treating a subject with moderate to severe hidradenitis suppurativa (HS) encompassing the determination of differential gene expression to characterize HS severity followed by administration of a treatment specific for the stage of HS severity characterized in the subject.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: September 13, 2022
    Assignee: The George Washington University
    Inventors: Victoria Shanmugam, Derek Jones
  • Patent number: 11427873
    Abstract: A method for characterizing tumor response to immune checkpoint blockade therapy, comprising: (i) obtaining tissue from the tumor; (ii) measuring, using the tissue, expression of one or more cell proliferation gene markers; (iii) determining, based on the measured expression of the one or more cell proliferation gene markers, a proliferation profile of the tumor; (iv) predicting, based on the determined proliferation profile, response of the tumor to immune checkpoint blockade therapy; and (v) determining, by a physician using the predicted response of the tumor to immune checkpoint blockade therapy, a therapy for the tumor.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 30, 2022
    Assignee: OmniSeq, Inc.
    Inventors: Carl Morrison, Sarabjot Pabla, Jeffrey Conroy, Sean Glenn
  • Patent number: 11414703
    Abstract: Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also disclosed are methods for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones, methods for selecting a treatment to treat an animal infected with a Dirofilaria spp. nematode, and kits for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: August 16, 2022
    Assignees: Elanco US Inc.
    Inventors: Roger K. Prichard, Catherine Bourguinat, Timothy G. Geary
  • Patent number: 11414708
    Abstract: Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: August 16, 2022
    Assignee: Decipher Biosciences, Inc.
    Inventors: Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Shuang G. Zhao, Sei-Won Laura Chang, Felix Y. Feng
  • Patent number: 11401559
    Abstract: Methods and kits are provided for screening a patient for bladder cancer. Embodiments include those involving centromeric probes to chromosomes 3, 7, and 10 and a locus-specific probe to 5p15.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: August 2, 2022
    Assignee: LEICA BIOSYSTEMS NEWCASTLE LTD
    Inventors: Saskia Schoenmakers, Harry Schrickx, Herman Volkers
  • Patent number: 11396678
    Abstract: Disclosed herein are methods and kits for identifying a subject as having breast cancer. Also provided herein are methods and kits for determining the prognosis of a subject having breast cancer and for determining the progression of breast cancer in a subject.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 26, 2022
    Assignees: The Regent of the University of California, YouHealth Oncotech, Limited
    Inventors: Kang Zhang, Rui Hou, Lianghong Zheng
  • Patent number: 11384395
    Abstract: This invention intends to develop many DNA markers for a plant of the genus Fragaria and detect powdery mildew resistance with high precision by using the many DNA markers. The marker associated with powdery mildew resistance in a plant of the genus Fragaria comprises a continuous nucleic acid region sandwiched between the nucleotide sequence as shown in SEQ ID NO: 1 and the nucleotide sequence as shown in SEQ ID NO: 19 in the chromosome of the plant of the genus Fragaria.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: July 12, 2022
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Hiroaki Koishihara, Hiroyuki Enoki, Masayoshi Muramatsu, Satoru Nishimura, Susumu Yui, Masanori Honjo
  • Patent number: 11345949
    Abstract: Provided herein is technology relating compositions and methods for analysis of methylated DNA from a subject. The technology also relates to use of endogenous methylated DNAs as internal controls for marker gene methylation assays.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 31, 2022
    Assignee: Exact Sciences Corporation
    Inventors: Hatim T. Allawi, Graham P. Lidgard
  • Patent number: 11345965
    Abstract: The invention pertains to analyzing the levels of DNA methylation at specific genetic loci to detect specific body fluids, for example, vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, or blood or blood cells. Particularly, the levels of methylation of DNA at the genetic loci corresponding to SEQ ID NOs: 1, 6, 11, and 16, more particularly, SEQ ID NOs: 25, 26, 27, and 28, are used to detect vaginal secretions or vaginal epithelial cells, semen or sperms, saliva or buccal epithelial cells, and blood or blood cells, respectively. The level of methylation at the specific loci can be determined by sequencing of the amplicons produced using specific primers designed to amplify the specific loci. Kits containing the primers and reagents for carrying out the methods disclosed herein are also provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 31, 2022
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Bruce McCord, Quentin Gauthier, Sohee Cho
  • Patent number: 11326214
    Abstract: The invention provides methods and compositions for the detection of Chlamydia trachomatis in a test sample. Its presence or absence in the sample is determined by nucleic acid based testing methods using primers and/or probes and or molecular beacons that bind to the 23S ribosomal genes or gene transcripts.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 10, 2022
    Assignee: Talis Biomedical Corporation
    Inventors: Andrea Dedent, Matt Lee, Shuyuan Ma, Hedia Maamar
  • Patent number: 11319602
    Abstract: A probe combination for detecting cancer includes one or more sets of partial hepatitis B virus (HBV) targeting probes. When sequences of each of the sets of partial HBV targeting probes are aligned, an overall sequence of the aligned set of probes matches a reference sequence of a genome of a HBV genotype or a direct repeat (DR) region on the genome. In the aligned set of probes, each of the probes overlap with one or two adjacent probes by a portion of a length of the probe. The probe combination may further includes one or more sets of hotspot gene targeting probes targeting cancer hotspot genes such as CTNNB1, TERT, and TP53 genes, one or more sets of exogenous gene targeting probes targeting portions of a lambda phage genome, and endogenous gene targeting probes targeting endogenous genes such as GAPDH and GdX genes.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 3, 2022
    Assignee: TCM BIOTECH INTERNATIONL CORP.
    Inventors: You-Yu Lin, Ya-Chun Wang, Sheng-Tai Tzeng
  • Patent number: 11299784
    Abstract: The present invention relates to a method for predicting the degree of weight loss attainable by applying one or more dietary interventions to a subject and/or the degree of maintenance of weight loss following one or more dietary interventions; which method comprises determining the level of microRNA-486 (miR-486) in one or more samples obtained from the subject; and/or determining the nucleotide of the subject at one or more polymorphic positions genetically linked to miR-486.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: April 12, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Armand Valesia, Jorg Hager, Jerome Carayol
  • Patent number: 11286527
    Abstract: The present invention relates to methods for detecting a genetic deletion at the SHOX locus of a horse, where the presence of such a genetic deletion indicates that the horse is a carrier of disease-causing mutation that can lead to skeletal atavism. The invention further provides nucleic acid primers and probes for use in methods for detecting the presence or absence of disease-causing genetic deletion at the SHOX locus of a horse.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 29, 2022
    Assignees: CAPILET GENETICS AB, UNIVERSITY OF WASHINGTON
    Inventors: Sofia Mikko, Leif Andersson, Gabriella Lindgren, Carl-Johan Rubin, Bhanu Chowdhary, Terje Raudsepp, Evan E. Eichler, John Huddleston, Maika Malig
  • Patent number: 11268133
    Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: March 8, 2022
    Assignee: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce A. Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
  • Patent number: 11268148
    Abstract: Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA and chromatin target of PRMT1 (CHTOP).
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: March 8, 2022
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventor: Raghavendra G. Mirmira